Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Summit Therapeutics PLC (NASDAQ:SMMT)

12.69
Delayed Data
As of 4:00pm ET
 +0.45 / +3.68%
Today’s Change
6.85
Today|||52-Week Range
19.75
+48.25%
Year-to-Date
Summit Therapeutics Stock Gets Smoked After IPO Pricing
Sep 14 / TheStreet.com - Paid Partner Content
Sarepta's Golodirsen Positive in DMD Study, Shares Soar
Sep 07 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close12.24
Today’s open12.24
Day’s range12.08 - 12.69
Volume43,703
Average volume (3 months)18,577
Market cap$151.6M
Dividend yield--
Data as of 4:00pm ET, 09/20/2017

Growth & Valuation

Earnings growth (last year)-5.90%
Earnings growth (this year)+66.29%
Earnings growth (next 5 years)--
Revenue growth (last year)+166.82%
P/E ratio--
Price/Sales46.76
Price/Book--

Competitors

 Today’s
change
Today’s
% change
CEMPCempra Inc0.000.00%
VRNAVerona Pharma PLC-0.26-1.71%
NTECIntec Pharma Ltd-0.05-0.58%
ACRXAcelRx Pharmaceutica...0.000.00%
Data as of 4:00pm ET, 09/20/2017

Financials

Next reporting dateDecember 14, 2017
EPS forecast (this quarter)-$0.47
Annual revenue (last year)$3.1M
Annual profit (last year)-$28.5M
Net profit margin-922.36%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Executive Director
Glyn O. Edwards
Chief Operating &
Medical Officer
David Roblin
Corporate headquarters
Abingdon, Oxfordshire

Forecasts